Posted by Michael Wonder on 29 Mar 2022
European Medicines Agency commences review of novel gene therapy candidate etranacogene dezaparvovec for people with haemophilia B
29 March 2022 - Marketing authorisation application for etranacogene dezaparvovec will be reviewed under accelerated assessment and has the potential to be the first gene therapy for patients living with haemophilia B.
CSL Behring today announced that the EMA has accepted the marketing authorisation application for etranacogene dezaparvovec (EtranaDez) under its accelerated assessment procedure.
Read CSL Behring press release
